{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:11:03Z","timestamp":1760037063896,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>Over the past century of research, it has become increasingly evident that glucagon should no longer be regarded solely as a counter-regulatory hormone to insulin. Its role in the pathophysiology of metabolic disorders\u2014including diabetes, obesity, and non-alcoholic fatty liver disease\u2014appears to be critical. Hyperglucagonemia is a common feature across several metabolic conditions, not only in adults but also in pediatric populations, suggesting that glucagon may represent both a pathogenic factor and a potential therapeutic target in metabolic disease. Accordingly, therapeutic strategies have been developed that either inhibit or enhance glucagon activity, depending on the clinical context, and some of these approaches are being applied in pediatric care as well. This review aims to provide a comprehensive overview of the pathophysiological role of glucagon in metabolic diseases, synthesizing recent findings that support novel hypotheses for the management and prevention of these conditions.<\/jats:p>","DOI":"10.3390\/pediatric17050104","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:06:53Z","timestamp":1759932413000},"page":"104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives"],"prefix":"10.3390","volume":"17","author":[{"given":"Giada","family":"Di Pietro","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University G. d\u2019Annunzio, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University G. d\u2019Annunzio, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-9306","authenticated-orcid":false,"given":"Angelika","family":"Mohn","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University G. d\u2019Annunzio, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"170942","DOI":"10.1016\/j.peptides.2023.170942","article-title":"Glucagon 100 years. Important, but still enigmatic","volume":"161","author":"Holst","year":"2023","journal-title":"Peptides"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-8587(22)00349-7","article-title":"Glucagon, from past to present: A century of intensive research and controversies","volume":"11","author":"Scheen","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Holst, J.J., and Wewer Albrechtsen, N.J. (2019). Methods and Guidelines for Measurement of Glucagon in Plasma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215416"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/jdi.13986","article-title":"A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon-derived peptide levels","volume":"14","author":"Kobayashi","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The New Biology and Pharmacology of Glucagon","volume":"97","author":"Finan","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Galsgaard, K.D., Pedersen, J., Knop, F.K., Holst, J.J., and Albrechtsen, N.J.W. (2019). Glucagon Receptor Signaling and Lipid Metabolism. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00413"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nature22363","article-title":"Structure of the full-length glucagon class B G-protein-coupled receptor","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcdb.2020.01.006","article-title":"Pancreatic \u03b1-cells\u2014The unsung heroes in islet function","volume":"103","author":"Wendt","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"F469","DOI":"10.1152\/ajprenal.00560.2015","article-title":"Glucagon actions on the kidney revisited: Possible role in potassium homeostasis","volume":"311","author":"Bankir","year":"2016","journal-title":"Am. J. Physiol-Ren. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1152\/physrev.1976.56.4.778","article-title":"Physiology and pathophysiology of glucagon","volume":"56","author":"Unger","year":"1976","journal-title":"Physiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.physbeh.2010.03.019","article-title":"Glucagon regulation of energy metabolism","volume":"100","author":"Heppner","year":"2010","journal-title":"Physiol. Behav."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-023-00817-4","article-title":"Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases","volume":"19","author":"Andersen","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/dbi22-0004","article-title":"The Liver\u2013\u03b1-Cell Axis in Health and in Disease","volume":"71","author":"Elmelund","year":"2022","journal-title":"Diabetes"},{"key":"ref_14","first-page":"141","article-title":"Pancreatic Extracts in the Treatment of Diabetes Mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can. Med. Assoc. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0026-0495(78)90291-3","article-title":"Role of glucagon in the pathogenesis of diabetes: The status of the controversy","volume":"27","author":"Unger","year":"1978","journal-title":"Metabolism"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14972","DOI":"10.1073\/pnas.1205983109","article-title":"Metabolic manifestations of insulin deficiency do not occur without glucagon action","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI113593","article-title":"The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas","volume":"82","author":"Samols","year":"1988","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.0510790103","article-title":"The unique cytoarchitecture of human pancreatic islets has implications for islet cell function","volume":"103","author":"Cabrera","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/dbi20-0016","article-title":"Blood Flow in the Pancreatic Islet: Not so Isolated Anymore","volume":"69","author":"Caicedo","year":"2020","journal-title":"Diabetes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ncb951","article-title":"Islet \u03b2-cell secretion determines glucagon release from neighbouring \u03b1-cells","volume":"5","author":"Ishihara","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00125-008-1103-z","article-title":"Insulin secretion from human beta cells is heterogeneous and dependent on cell-to-cell contacts","volume":"51","author":"Wojtusciszyn","year":"2008","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jdi.12841","article-title":"Human pancreatic \u03b1- to \u03b2-cell area ratio increases after type 2 diabetes onset","volume":"9","author":"Fujita","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin Secretion Depends on Intra-islet Glucagon Signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2337\/dc08-0575","article-title":"Too Much Glucagon, Too Little Insulin","volume":"31","author":"Brown","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s00125-014-3264-2","article-title":"Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals","volume":"57","author":"Bagger","year":"2014","journal-title":"Diabetologia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cld.2018.07.001","article-title":"Nonalcoholic Liver Disease in Children and Adolescents","volume":"22","author":"Smith","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"G91","DOI":"10.1152\/ajpgi.00216.2017","article-title":"Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes","volume":"314","author":"Junker","year":"2018","journal-title":"Am. J. Physiol-Gastrointest. Liver Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mehy.2015.10.029","article-title":"Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia","volume":"86","author":"Suppli","year":"2016","journal-title":"Med. Hypotheses"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/db19-0715","article-title":"Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis","volume":"69","author":"Suppli","year":"2020","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00184","DOI":"10.1002\/edm2.184","article-title":"Perspectives on youth-onset nonalcoholic fatty liver disease","volume":"3","author":"Cioffi","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2015-3885","article-title":"Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents with Obesity and Type 2 Diabetes","volume":"101","author":"Manell","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2337\/db20-0440","article-title":"Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia","volume":"70","author":"Lubaczeuski","year":"2021","journal-title":"Diabetes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ng0395-299","article-title":"A missense mutation in the glucagon receptor gene is associated with non\u2013insulin\u2013dependent diabetes mellitus","volume":"9","author":"Hager","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/hmg\/4.9.1609","article-title":"Mutation of the glucagon receptor gene and diabetes mellitus in the UK: Association or founder effect?","volume":"4","author":"Gough","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Veneti, S., Grammatikopoulou, M.G., Kintiraki, E., Mintziori, G., and Goulis, D.G. (2023). Ketone Bodies in Diabetes Mellitus: Friend or Foe?. Nutrients, 15.","DOI":"10.3390\/nu15204383"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ceb.2015.02.003","article-title":"Acetyl-CoA and the regulation of metabolism: Mechanisms and consequences","volume":"33","author":"Shi","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2337\/diab.25.9.776","article-title":"Effect of Diabetes Mellitus and Insulin on the Turnover and Metabolic Response to Ketones in Man","volume":"25","author":"Sherwin","year":"1976","journal-title":"Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0022-2275(20)34462-X","article-title":"Ketone body kinetics in humans: The effects of insulin-dependent diabetes, obesity, and starvation","volume":"25","author":"Hall","year":"1984","journal-title":"J. Lipid Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000369702","article-title":"Hyperketonemia (Acetoacetate) Upregulates NADPH Oxidase 4 and Elevates Oxidative Stress, ICAM-1, and Monocyte Adhesivity in Endothelial Cells","volume":"35","author":"Jain","year":"2015","journal-title":"Cell Physiol. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.freeradbiomed.2016.03.020","article-title":"Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes","volume":"95","author":"Jain","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00125-016-3965-9","article-title":"Glucagon is the key factor in the development of diabetes","volume":"59","author":"Lee","year":"2016","journal-title":"Diabetologia"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Han, C., Zhu, W., Yang, G., Peng, X., Mehta, S., Zhang, J., Chen, L., and Liu, Y. (2021). Glucagon Potentiates Insulin Secretion Via \u03b2-Cell GCGR at Physiological Concentrations of Glucose. Cells, 10.","DOI":"10.3390\/cells10092495"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dbi19-0004","article-title":"Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes","volume":"69","author":"Finan","year":"2020","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"170296","DOI":"10.1016\/j.peptides.2020.170296","article-title":"Glucagon-based therapy: Past, present and future","volume":"127","author":"Patil","year":"2020","journal-title":"Peptides"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbrc.2019.03.148","article-title":"Glucagon receptor antagonism increases mouse pancreatic \u03b4-cell mass through cell proliferation and duct-derived neogenesis","volume":"512","author":"Gu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","article-title":"Glucagon receptor antagonist volagidemab in type 1 diabetes: A 12-week, randomized, double-blind, phase 2 trial","volume":"28","author":"Pettus","year":"2022","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients","volume":"86","author":"Damholt","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00125-021-05480-w","article-title":"Youth-onset type 2 diabetes: Translating epidemiology into clinical trials","volume":"64","author":"Pyle","year":"2021","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"TODAY Study Group (2012). A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. N. Engl. J. Med., 366, 2247\u20132256.","DOI":"10.1056\/NEJMoa1109333"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S2213-8587(16)00039-5","article-title":"Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus","volume":"4","author":"Frandsen","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1932296816647976","article-title":"Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial","volume":"10","author":"Ilkowitz","year":"2016","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00125-014-3486-3","article-title":"The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes","volume":"58","author":"Fredheim","year":"2015","journal-title":"Diabetologia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/dom.12944","article-title":"Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of Liraglutide to Insulin in Patients with Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7503\/17\/5\/104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:34Z","timestamp":1760035834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/17\/5\/104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pediatric17050104"],"URL":"https:\/\/doi.org\/10.3390\/pediatric17050104","relation":{},"ISSN":["2036-7503"],"issn-type":[{"type":"electronic","value":"2036-7503"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}